Stocks have a way of telling stories, of embodying the zeitgeist. NVIDIA (NASDAQ:NVDA) is proof – a generative AI powerhouse propelling into trillionaire territory with gusto — a familiar tale of technological prowess meets investor adulation.
The Unusual Biopharma Contender: Eli Lilly (LLY)
Source: shutterstock.com/Michael Vi
Eli Lilly (NYSE:LLY) enters the fray, an unlikely biopharma contender striding confidently against convention. Morgan Stanley’s Terence Flynn ponders— could LLY break the trillion-dollar ceiling? “We continue to see a path for further upside,” he notes.
Pharma behemoths rarely ascend beyond a trillion, but Eli Lilly’s star burns bright. Sales of the novel obesity drug Zepbound, launched in December, soar to $175.8 million, eclipsing $75 million forecasts. Diabetes med Mounjaro rakes in $2.2 billion, trumping $1.73 billion estimates.
Net income spikes, reaching $2.19 billion in Q4 2023, a 13% year-over-year surge at $1.94 billion.
Underdog Turned Titan: Taiwan Semiconductor Manufacturing Company (TSM)
Source: sdx15 / Shutterstock.com
Taiwan Semiconductor Manufacturing Company (NYSE:TSM), an underdog turned titan, charts a bold course.
While Q4 2023 saw dips in revenue and net income year-over-year, TSMC surpassed projections. Major clients like Apple and NVIDIA bolster TSMC’s ambitions, steering the firm toward a lucrative future, brushing off economic headwinds.
2023 revealed over 20% growth in Wall Street performance. TSMC’s finale in Q4 boasts a 14.4% revenue leap from Q3, riding the crest of their 3-nanometer tech surge.
Anticipated mass production exceeding one trillion transistors by 2030 positions TSMC to fortify NVIDIA’s expansion, paving its path towards a trillion-dollar market cap.
Persistence and Perseverance: Tesla (TSLA)
Source: Sheila Fitzgerald / Shutterstock.com
Tesla (NASDAQ:TSLA) weathers the storm, a phoenix poised for rebirth. The EV juggernaut aims for the trillion-dollar pantheon once more, trudging through rocky terrain.
Q4 2024 unveils a glimmer of hope, with a 3% surge to $25.17 billion in earnings. Projections hint at a 20% to 25% sales uptick, translating into 2.2 to 2.3 million vehicles on the road. CEO Elon Musk, the wizard behind the curtains, pulls strings to engineer 1.8 million global deliveries.
Equally essential is the road forward, guided by analyst Dan Ives' $350 price target. If Tesla reclaims its trillion-dollar stature, the Magnificent Seven could swell to an Octet. In Tesla's playbook, persistence spells success.
